Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

H. Lundbeck Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

H. Lundbeck şirketinin toplam hissedar öz sermayesi DKK23.2B ve toplam borcu DKK3.7B olup, bu da borç-öz sermaye oranını 16% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK39.1B ve DKK15.9B dir. H. Lundbeck 'in FAVÖK'ü DKK3.5B faiz karşılama oranı -17.7 dur. Şirketin DKK6.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

16.0%

Borç/özkaynak oranı

DKK 3.72b

Borç

Faiz karşılama oranı	-17.7x
Nakit	DKK 6.15b
Eşitlik	DKK 23.22b
Toplam yükümlülükler	DKK 15.87b
Toplam varlıklar	DKK 39.09b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HLUNBC 'nin kısa vadeli varlıkları ( DKK15.2B ) kısa vadeli yükümlülüklerini ( DKK8.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: HLUNBC şirketinin kısa vadeli varlıkları ( DKK15.2B ) uzun vadeli yükümlülüklerini ( DKK7.8B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HLUNBC şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: HLUNBC şirketinin borç/öz sermaye oranı son 5 yılda 4.8% seviyesinden 16% seviyesine yükseldi.

Borç Kapsamı: HLUNBC 'nin borcu işletme nakit akışı ( 124% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: HLUNBC ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

H. Lundbeck Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin